| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/28/2013 | CA2481108C Tuberculosis vaccines including recombinant bcg strains expressing alanine dehydrogenase, serine dehydratase and/or glutamine synthetase |
| 05/28/2013 | CA2476935C Drug delivery system for subconjunctival administration of fine particles |
| 05/28/2013 | CA2464353C Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| 05/28/2013 | CA2455100C Mediators of hedgehog signaling pathways,compositions and uses related thereto |
| 05/28/2013 | CA2453301C Synthetic double-stranded oligonucleotides for specific inhibition of gene expression |
| 05/28/2013 | CA2443372C Immunotherapeutic combinations for the treatment of tumors that over-express gangliosides |
| 05/28/2013 | CA2440831C Combination therapy using cd40 and cd20 ligands |
| 05/28/2013 | CA2427902C Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 05/28/2013 | CA2427661C Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
| 05/23/2013 | WO2013075048A1 Methods of treating epidermal growth factor deletion mutant viii related disorders |
| 05/23/2013 | WO2013074820A1 Immunogenic tumor associated stromal cell antigen peptides and methods of their use |
| 05/23/2013 | WO2013074633A1 Uracil derivatives as axl and c-met kinase inhibitors |
| 05/23/2013 | WO2013074594A1 Combination therapy of hsp90 inhibitors with braf inhibitors |
| 05/23/2013 | WO2013074581A1 Fructose-1,6-biphosphatases as new targets for diagnosing and treating breast cancer brain metastasis |
| 05/23/2013 | WO2013074517A1 Kinase protein binding inhibitors |
| 05/23/2013 | WO2013074489A1 Conjugates of gm-csf and il-7, compositions and methods related thereto |
| 05/23/2013 | WO2013073698A1 Cxcr4 activity inhibiting peptide and application thereof |
| 05/23/2013 | WO2013073576A1 Nucleic acid molecule for inhibiting activity of rnai molecule |
| 05/23/2013 | WO2013073085A1 Apoptosis inducer |
| 05/23/2013 | WO2013072836A1 Use of protein s for treating cancer |
| 05/23/2013 | WO2013072502A1 Pharmaceutically active pyrazine derivatives |
| 05/23/2013 | WO2013072415A1 Binding molecules for bcma and cd3 |
| 05/23/2013 | WO2013072406A1 Binding molecules for bcma and cd3 |
| 05/23/2013 | WO2013072392A1 Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2-signal transducer and activator of transcription 5 pathway |
| 05/23/2013 | WO2013072044A1 Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer |
| 05/23/2013 | WO2013072015A1 Morpholinyl benzotriazine for use in cancer therapy |
| 05/23/2013 | WO2013071865A1 Kinase modulating compounds, compositions containing the same and use thereof |
| 05/23/2013 | WO2013071727A1 Anti-tumor traditional chinese medical composition |
| 05/23/2013 | WO2013071724A1 Baicalin metal complex and preparation method and application thereof |
| 05/23/2013 | WO2013071715A1 Histone deacetylase inhibitors and synthetic method thereof and use thereof in manufacture of medicaments |
| 05/23/2013 | WO2013071698A1 Three-ring pi3k and/or mtor inhibitor |
| 05/23/2013 | WO2013071697A1 Aminoquinazoline derivatives and their salts and methods of use |
| 05/23/2013 | WO2013071696A1 Use of five normal bases in humans for preparation of tumour drugs |
| 05/23/2013 | WO2013071415A1 Targeting the rb pathway for the prevention of cancer |
| 05/23/2013 | WO2013049591A3 Dual inhibitor compounds and methods of use thereof |
| 05/23/2013 | WO2013048214A3 Novel heterocyclic derivatives and their uses |
| 05/23/2013 | WO2013048177A3 Selenophene-fused aromatic compound and manufacturing method thereof |
| 05/23/2013 | WO2013048116A3 Erythropoietin-derived peptide and use therefor |
| 05/23/2013 | WO2013048022A3 Α-type zinc- phthalocyanine nanowires having enhanced water solubility and water dispersibility, composite of an α-type zinc- phthalocyanine nanowire/phenothiazine, and method for preparing same |
| 05/23/2013 | WO2013037487A8 A particulate system for use in diminishing cell growth/inducing cell killing |
| 05/23/2013 | WO2013021260A3 Compounds from anisomeles heyneana |
| 05/23/2013 | WO2013019079A9 Composition containing 5-hydroxyindole compounds or sponge scalarispongia sp. extracts as active ingredients for prevention and treatment of cancer diseases |
| 05/23/2013 | WO2012169785A9 Symmetrically structured quinazoline derivatives |
| 05/23/2013 | WO2012165854A9 Long interfering dsrna simultaneously inducing an immune reaction and the inhibition of the expression of target genes |
| 05/23/2013 | WO2012145575A9 Therapy for leukemia |
| 05/23/2013 | US20130131317 Expression of secreted human alpha-fetoprotein in transgenic animals |
| 05/23/2013 | US20130131139 Ror1 as a gene target in acute lymphoblastic leukemia |
| 05/23/2013 | US20130131122 Fluro substituted Omega-Carboxyaryl Diphenyl Urea for the Treatment and Prevention of Diseases and Conditions |
| 05/23/2013 | US20130131038 N-containing heteroaryl derivatives as jak3 kinase inhibitors |
| 05/23/2013 | US20130131026 Compositions and methods for treating symptoms of inflammatory related conditions using a combination of an antihistamine and a stimulant |
| 05/23/2013 | US20130131013 Cyclodextrin-based polymers for therapeutics delivery |
| 05/23/2013 | US20130129691 Compositions For The Treatment Of Skin Conditions, Disorders Or Diseases And Methods Of Making And Using The Same |
| 05/23/2013 | US20130129680 Method for treating hepatitis c virus infection using quercetin-containing compositions |
| 05/23/2013 | US20130129678 Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer |
| 05/23/2013 | US20130129665 Cyclodextrin-based polymers for therapeutics delivery |
| 05/23/2013 | US20130129618 Egcg stabilized gold nanoparticles and method for making same |
| 05/23/2013 | US20130129614 Microorganisms for imaging and/or treatment of tumors |
| 05/23/2013 | CA2856103A1 Morpholinyl benzotriazine for use in cancer therapy |
| 05/23/2013 | CA2855950A1 Kinase modulating compounds, compositions containing the same and use thereof |
| 05/23/2013 | CA2855818A1 Methods of treating cancer |
| 05/23/2013 | CA2855746A1 Methods of treating epidermal growth factor deletion mutant viii related disorders |
| 05/23/2013 | CA2855675A1 Conjugates of gm-csf and il-7, compositions and methods related thereto |
| 05/23/2013 | CA2855619A1 Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2 - signal transducer and activator of transcription 5 pathway |
| 05/23/2013 | CA2854188A1 Combination therapy of hsp90 inhibitors with braf inhibitors |
| 05/23/2013 | CA2852697A1 Uracil derivatives as axl and c-met kinase inhibitors |
| 05/23/2013 | CA2851151A1 Aminoquinazoline derivatives and their salts and methods of use |
| 05/23/2013 | CA2850591A1 Binding molecules for bcma and cd3 |
| 05/23/2013 | CA2849196A1 Binding molecules for bcma and cd3 |
| 05/23/2013 | CA2845637A1 Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer |
| 05/22/2013 | EP2594644A1 Method for preparing novel hipsc by means of mirna introduction |
| 05/22/2013 | EP2594643A1 Method for producing novel hipsc by means of sirna introduction |
| 05/22/2013 | EP2594582A2 Peptide vaccines with Seq Id No: 110, 111, 387, 112, 394 114, 116, 117 or 121 for cancers expressing tumor-associated antigens |
| 05/22/2013 | EP2594581A2 Peptide vaccines with Seq Id No: 178, 174, 186 or 194 for cancers expressing tumor-associated antigens |
| 05/22/2013 | EP2594567A1 Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof |
| 05/22/2013 | EP2594566A1 Nitrogenated aromatic heterocyclic ring derivative |
| 05/22/2013 | EP2594555A1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR |
| 05/22/2013 | EP2594274A1 Novel hyaluronic acid decomposition-promoting factor and inhibitor thereof |
| 05/22/2013 | EP2593479A1 Superior efficacy of cd37 antibodies in cll blood samples |
| 05/22/2013 | EP2593471A1 Cyclotetrapeptides with pro-angiogenic properties |
| 05/22/2013 | EP2593467A1 Carbohydrate hapten-based anti-cancer vaccines and antibody drugs |
| 05/22/2013 | EP2593462A1 NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
| 05/22/2013 | EP2593458A1 Bicyclic pyrimidines |
| 05/22/2013 | EP2593455A1 Purine compounds selective for i3 p110 delta, and methods of use |
| 05/22/2013 | EP2593453A1 Azaindazole compounds |
| 05/22/2013 | EP2593450A1 Substituted imidazoquinoline derivatives as kinase inhibitors |
| 05/22/2013 | EP2593435A1 Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives |
| 05/22/2013 | EP2593142A1 Multifunctional antibody conjugates |
| 05/22/2013 | EP2593141A2 Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
| 05/22/2013 | EP2593139A2 Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer |
| 05/22/2013 | EP2593127A1 Anti-angiogenic agent and method of using such agent |
| 05/22/2013 | EP2593126A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases |
| 05/22/2013 | EP2593125A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases |
| 05/22/2013 | EP2593124A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases |
| 05/22/2013 | EP2593122A1 Peptide for use in the treatment of breast cancer and/or bone metastases |
| 05/22/2013 | EP2593118A2 Targeted nanoparticles for cancer and other disorders |
| 05/22/2013 | EP2593113A1 Cell therapy |
| 05/22/2013 | EP2593111A2 New compounds for treating cancer and other diseases |
| 05/22/2013 | EP2593104A2 Methods of treating and preventing/reducing the likelihood of mesial temporal lobe epilepsy (tle) |
| 05/22/2013 | EP2593101A2 Combination therapy using a ruthenium complex |
| 05/22/2013 | EP2593100A2 Method of treating refractory cancer |